Brisbane-based Ellume has announced the appointment of David Green as chief financial officer and company secretary and Mark Boyle as chief business officer.
Ellume is a digital diagnostics company focused on the detection of common illnesses.
The company said the new appointments strengthen its management ahead of US commercialisation and a potential ASX IPO later this year.
David Green joins the company with a background in pre-IPO and start-up businesses. He started his career with EY and has since gone on to CFO roles with a number of ASX-listed entities, including Sigma Pharmaceuticals and Alchemia.
Mark Boyle brings executive management experience in in-vitro diagnostic and biotechnology markets to his new role in the US.
“Mark and David both bring formidable experience and leadership to our expanding team,” said founder and managing director Dr Sean Parsons. “Mark’s experience in successfully scaling the sales of QuantiFERON in the US gives us confidence and a successful framework as we prepare to replicate this with our ellume·lab product, and David’s experience with public markets at Sigma, Alchemia and others is proving fundamental as we position the company to potentially transition onto the ASX later this year.”
Ellume received $US15 million from German biotech Qiagen in January as part of its strategic partnership to build on the QuantiFERON TB diagnostic business. Ellume also announced a global partnership with GSK in late 2018.